Novonesis (Novozymes A/S) (NVZMY) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Novonesis (Novozymes A/S) (NVZMY): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why NVZMY has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with NVZMY. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
The trailing figures come from adding H1 2026 to full-year 2025 and removing H1 2025. Reported net profit is held down by purchase-price amortization from the Chr. Hansen merger and Feed Enzyme Alliance deal: adjusted net profit excluding that amortization was EUR 929 million in 2025 and EUR 507 million in H1 2026, against reported net profit of EUR 584 million and EUR 371 million. That is why diluted EPS was EUR 0.80 in H1 2026 while adjusted EPS excluding amortization was EUR 1.09. Free cash flow before acquisitions was EUR 770 million in 2025, about 19% of sales, but should be lower relative to sales while capex runs at 12% to 14%.
Is there a 2030 forecast for NVZMY?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering NVZMY do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.
On the figures we hold as of October 2026, NVZMY trades at about 41.0 times trailing earnings and 24.5 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.
That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Novonesis (Novozymes A/S) can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move NVZMY from here
In short: the drivers cited most often are Food & Beverages momentum, Biofuels and the Energy business, Animal nutrition after the Feed Enzyme Alliance deal. The risk cited most often against it is the first risk is valuation and expectations: Novonesis was worth about DKK 191 billion (~EUR 25.6 billion) at the end of 2025 against EUR 1.54 billion of 2025 adjusted EBITDA, so a slowdown from the 7% to 8% growth now guided could hurt the shares more than the business.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the NVZMY is it a buy page. This page deliberately stops at the numbers.
Investing in Novonesis (Novozymes A/S) with AI
Connect the broker you already use and ask Walnut's AI how NVZMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Novonesis (Novozymes A/S) (NVZMY)?
+
There is no meaningful consensus price target for NVZMY, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does NVZMY have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move NVZMY?
+
The drivers and the risks are laid out on this page and in more depth on the NVZMY "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a October 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.